3b Blackbio Dx Ltd · NSE:3BBLACKBIO
3b Blackbio Dx — Kilpest India — Investor Presentation (May 2018)
20 slides from 3b Blackbio Dx's investor presentation, May 2018
Slide 1: Cover letter to BSE
KILPEST INDIA LIMITED REGD. OFFICE & FACTORY: SUREWIH QUALITY CERTIFICATION .• 0 8001 • aooo 7-C, INDUSTRIAL AREA, GOVINDPURA, BHOPAL - 462 023 (INDIA) Tel (91-755) 2586536, 2586537, 2586439 FAX NO. (91-755) 2580438 Emall kilpest@bsnl.in· visit us at : www.kilpest.com kilpestbpl@yahoo.co.in CIN: L24
Slide 2: Investor Presentation May 2018
Farmers trusted Agro-input partner for 44 years Reliable & affordable healthcare diagnostics solutions INVESTOR PRESENTATION MAY 2018
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Kilpest India Limited and 3B BlackBio Biotech India Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to
Slide 4: Kilpest Existing Products
Kilpest Existing Products Chemicals Biologicals No. of Products No. of Products • Insecticides - 70 • Bio pesticide - 07 • Antibacterials - 01 • Bio fungicide - 01 • Fungicides - 15 • Bio fertilizers - 05 • Herbicides - 11 • Bio nematicides - 01 • Public Health - 11 • Public Health - 02 • Microferti
Slide 5: Business Overview and Strengths
Business Overview and Strengths Experienced team & state of art facility located in center of India- with GST implementation this should give a boost to the company • 44yrs old Pesticide Formulation Company, well established in central India, strong brand equity in central India especially in Madhya
Slide 6: Financial Performance: Key Highlights
Financial Performance : Key Highlights Q4FY18, KILPEST (Consolidated) Q4 FY18 Q4 FY17 Q4 FY18, 58.38 551.88 84.03% 506.86% Net sales (net of Excise duty) 551.88 299.88 Q4FY17, 299.88 Profit before tax 100.46 11.83 Q4FY17, Profit after tax 58.38 9.62 9.62 Revenue PAT Paid up Equity share capital 640.
Slide 7: Financial Performance: Key Highlights
Financial Performance : Key Highlights FY18, FY18, KILPEST (Consolidated) FY18 FY17 2321.26 43.61% 342.60 202.68% Net sales (net of Excise duty) 2321.26 1616.33 FY17, 1616.33 Profit before tax 451.59 139.71 FY17, Profit after tax 342.60 113.19 113.19 Revenue PAT Paid up Equity share capital 640.81 6
Slide 8: Present Market Overview/Outlook
Present Market Overview/Outlook •The Company Sales Turnover is Rs 1556.22 lakhs which is marginally higher by 19.65% as compared to last year which was Rs 1300.65 and the PBT stands at Rs 56.89 lakhs which is higher by 109.69% as compared to last year which was Rs 27.13 Lakhs, despite very tough yea
Slide 9: Financial Highlights- 3B BlackBio Biotech (Q4 FY18)
Financial Highlights- 3B BlackBio Biotech (Q4 FY18) 111.46 203.29 117.14% 232.02% 93.62 33.57 Revenue EBITDA 54.36 102.85 400.49% 247.34% Q4 FY18 15.65 Q4 FY17 20.55 Rs. In Lakhs PBT PAT BCR ABL I JAK 2 I PML RARA I KRAS I HLA B27 I MDR TB I H1N1 Dengue I Chikungunya I HPV
Slide 10: Financial Highlights- 3B BlackBio Biotech (FY18)
Financial Highlights- 3B BlackBio Biotech (FY18) 433.13 765.04 142.35% 187.66% 315.68 150.57 Revenue EBITDA 290.6 394.7 250.60% 222.17% FY18 112.58 90.2 FY17 Rs. In Lakhs PBT PAT BCR ABL I JAK 2 I PML RARA I KRAS I HLA B27 I MDR TB I H1N1 Dengue I Chikungunya I HPV
Slide 11: Industry Potential- Molecular Diagnostics
Industry Potential- Molecular Diagnostics • The global IVD Market US$ 54.7 billion in the year 2015 (CAGR of 5-6%)1 Highest Growth Rate • Molecular Diagnostic Market US$ 7 billion (CAGR of 10-15%)2 • Indian diagnostics industry was around Rs. 377 billion in 2014-2015 and will continue to grow by a C
Slide 12: Demand drivers for the Indian Diagnostic Industry
Demand drivers for the Indian Diagnostic Industry • Increased focus on advanced diagnostics • changing costs and quality of healthcare, • rising medical tourism, • evolution of disease profiles, • technology as a driving force, • increase in evidence-based treatments / Drug response monitoring • cha
Slide 13: Molecular Diagnostics
Molecular Diagnostics • The process of identifying a disease by studying molecules, such as proteins, DNA, and RNA, in a tissue or fluid. • Molecular diagnostics is a technique used to analyze biological markers in the genome and proteome—the individual’s genetic code and how their cells express the
Slide 14: Winning Strategy
Winning Strategy • Proprietary kits designed, developed & validated in-house • Well accepted assays across wide customer base PAN India • Continuous R&D initiatives for International quality product • Wide range of Diagnostic kits- Infectious, Oncology & Genetics • Import substitution with price adv
Slide 15: New Customers added in Q4 2017-18
New Customers added in Q4 2017-18 • Two Regional Labs in Kolkata • A Leading Diagnostic Lab in Pune • A Diagnostic Lab in Mumbai • A National Diagnostic Lab in Mumbai • A Leading Medical Hospital in Chennai • Few other tests started by existing customers. * Names withheld due to reason of customer c
Slide 16: Products in Pipeline
Products in Pipeline • MRSA Detection- Methicillin-resistant Staphylococcus aureus may cause life-threatening infections in some people as it is resistant to commonly used antibiotics including Methicillin, it can be harder to treat or become worse if the right treatment is delayed. MRSA is one of t
Slide 17: Facility Expansion
Facility Expansion Next Gen Sequencing (NGS) Facility Cell Culture Facility • Company is exploring opportunities into Clinical Genetics • Availability of specific Cell lines is very crucial, costly & and has acquired a Next-Generation Sequencing System limited in Molecular Diagnostic research (NGS)
Slide 18: PCR based Molecular Diagnostic Kit Range
PCR based Molecular Diagnostic Kit Range Genetics & TRUPCR® BCR-ABL Qualitative Kit – M m µ Detection and differentiation of BCR-ABL major (M), minor (m) and micro (µ) transcripts Oncology TRUPCR® BCR-ABL Quantitative Kit – M m µ Detection, differentiation and quantitation of BCR-ABL major (M), mino
Slide 19: TRUPCR Kit Range: Drug Resistance, Blood-borne Viruses, Tropical Diseases
Drug Resistance TRUPCR® Rifampicin Resistant MTB Detection Kit Extraction of MTBC DNA from any sample type, detection of MTB & Rifampicin resistance mutations Coagulation TRUPCR® Factor V Leiden mutation. Detection of Factor V Leiden mutation on real-time PCR Prognostic Panel Blood-borne TRUPCR® HBV
Slide 20: Kilpest India Limited / 3B BlackBio Biotech India Limited
For further information, please contact: KILPEST INDIA LIMITED 3B BLACKBIO BIOTECH INDIA LIMITED 7-C Industrial Area , Govindpura, Bhopal- 462023[M.P.] INDIA 7-C Industrial Area , Govindpura, Bhopal- 462023 [M.P.] INDIA Phone :: +91-755-2586536 Phone :: +91-755-4077847 Fax :: +91-755-2580438 Fax ::